To view this email as a web page, click here.
 
Diabetes Drugs and CV Protection: An 8-question Quiz
How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell.
Read more
 
TGs and EPA: A New Chapter in CV Disease Prevention
The REDUCE-IT trial showed that EPA lowers the relative risk of hard CV endpoints. Johns Hopkins cardiologists put the trial in perspective.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.